Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jun 19, 2014

BIND, Roche Collaborate to Discover Nanomedicines

  • BIND Therapeutics has entered into a research agreement with Roche to discover nanomedicines for the treatment of diseases in therapeutic areas outside of oncology. The collaboration will focus on combining BIND’s Accurin technology with Roche’s therapeutic payloads and targeting ligands.

    “By combining BIND’s Medicinal Nanoengineering® platform with Roche’s deep expertise in disease areas with high unmet medical need, this agreement further validates the wide-ranging potential for our technology and facilitates extending our platform into new therapeutic areas,” said Scott Minick, CEO of BIND Therapeutics.

    In the past, BIND has announced collaborations with Amgen, Pfizer, and AstraZeneca to develop Accurins based on therapeutic payloads from their product pipelines. Last year, BIND entered into a global collaboration agreement with Amgen to develop and commercialize a kinase inhibitor nanomedicine for treating a range of solid tumors based on BIND's platform and Amgen's undisclosed kinase inhibitor. As part of the agreement, Amgen has to exercise its option to select a novel Accurin candidate for further development by July 2014 to allow for completion of the research plan.

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »